Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy

Anti-viral immunity presents a major hurdle for systemically administered oncolytic viruses (OV). Intratumoral OV therapy has a potential to overcome this problem through activation of anti-tumor immune response, with local and abscopal effects. However, the effects of anti-viral immunity in such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricca, Jacob M., Oseledchyk, Anton, Walther, Tyler, Liu, Cailian, Mangarin, Levi, Merghoub, Taha, Wolchok, Jedd D., Zamarin, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079372/
https://www.ncbi.nlm.nih.gov/pubmed/29478729
http://dx.doi.org/10.1016/j.ymthe.2018.01.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079372/
https://www.ncbi.nlm.nih.gov/pubmed/29478729
http://dx.doi.org/10.1016/j.ymthe.2018.01.019

Ejemplares similares